



EMPOWERING
MUSCLE
EMPOWERING
LIVES

Sarcomere Directed Therapies



Nefertari, diagnosed with heart failure



Jillian, diagnosed with HCM



Chuck, diagnosed with ALS

Forward-Looking Statements

This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements related Cytokinetics’ research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of clinical trials, projections regarding growing prevalence, low survival rates and market opportunity in heart failure, hypertrophic cardiomyopathy (HCM) or amyotrophic lateral sclerosis (ALS); projections regarding the size of the addressable patient population for *omecamtiv mecarbil*, *aficamten* or *rel-desemtiv*; Cytokinetics’ commercial readiness for *omecamtiv mecarbil*; the likelihood of approval and timing for regulatory approval of *omecamtiv mecarbil* or any of our other drug candidates; the submission or acceptance of filing of a new drug application (NDA) to or by the FDA for *omecamtiv mecarbil* in 2021; the timing of an interim analysis of COURAGE-ALS, a phase 3 clinical trial of *rel-desemtiv* or the timing of commencement of SEQUOIA-HCM, a phase 3 clinical trial of *aficamten*; our ability to fully enroll COURAGE-ALS or SEQUOIA-HCM; Cytokinetics’ cash expenditures or runway; the timing or availability of additional sale proceeds or loan disbursements from Royalty Pharma; interactions with the FDA; the properties, potential benefits and commercial potential of *aficamten*, *omecamtiv mecarbil*, *rel-desemtiv* and Cytokinetics’ other drug candidates; the activities of Ji Xing under our collaboration agreements therewith or our ability to earn any additional milestone payments or royalties pursuant thereto. Such statements are based on management's current expectations; but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur unanticipated research, development and other costs or be unable to obtain financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. These forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission (the “SEC”).

Sarcomere Directed Therapies

OUR MISSION

To bring forward new medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

VISION 2025

Leading with Science,
Delivering for Patients

As always, we will support disease advocacy groups elevating the patient voice and live by our values of integrity, fairness and compassion in all that we do.

Our vision is to be the leading muscle biology biopharma company that meaningfully improves the lives of patients with diseases of impaired muscle function through access to our pioneering medicines

Achieve regulatory approvals for at least two drugs arising from our pipeline

Build commercial capabilities to market and sell our medicines reflective of their innovation and value

Generate sustainable and growing revenues from product sales

Double our development pipeline to include ten therapeutic programs

Expand our discovery platform to muscle energetics, growth and metabolism


Be the science-driven company people want to join and partner with

Executing On Our Vision




Sarcomere Directed Drug Development

The sarcomere is a molecular structure found in skeletal and cardiac muscle that enables cardiac myocytes to contract and generate force



Pipeline of Novel Muscle-Directed Drug Candidates



Sarcomere Directed Drug Development

CARDIAC MUSCLE


Omecamtiv Mecarbil

Aficamten

Contractile Dysfunction Underlies Cardiac Diseases

Increased / Preserved Cardiac Contractility

- Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
- **Obstructive Hypertrophic Cardiomyopathy (oHCM)**
- Heart Failure with Preserved Ejection Fraction (certain HFrEF subsets)



Decreased Cardiac Contractility


- **Heart Failure with Reduced Ejection Fraction (HFrEF)**
- Genetic Dilated Cardiomyopathy
- Pulmonary Hypertension with Right Ventricular Heart Failure

Omecamtiv Mecarbil

Heart Failure Is a Public Health Epidemic

~6.5M Americans ≥20 years of age have HF; 1M new HF cases occur annually¹

High cost burden driven by hospitalizations; mean cost for each hospital stay ~\$17K²



HF: heart failure

1. Benjamin EJ, et al. *Circulation*. 2018;137:e67-e492;

2. Gaziano et al, *AMA Cardiol*. 2016;1(6):666-672. doi:10.1001/jamacardio.2016.1747

3. Urbich, M., Globe, G., Pantiri, K. et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). *PharmacoEconomics* 38, 1219–1236 (2020). <https://doi.org/10.1007/s40273-020-00952-0>

3. Heidenreich PA, Albert NM, Allen LA, Blumke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail*. 2013;6(3):606–19. <https://doi.org/10.1161/HHF.0b013e318291329a>.

4. Benjamin EJ, et al. *Circulation*. 2019;139:e56-e528;

5. Davis JD, et al. *Am J Med*. 2017;130:93.e9-93.e28. (a) In an investigational study of patients with an index hospitalization for HF from California, New York, and Florida from 2007–2011 (N=547,088).

6. Shah KS, et al. *J Am Coll Cardiol*. 2017;70:2476-2486. (b) Among HFREF patients (n=18,398), HFrEF patients (n=3285), and HFpEF patients (n=18,299) in the GWTG-HF registry, a study of patients on Medicare and Medicaid services (N=39,982). GWTG-HF, Get With the Guidelines®-Heart Failure

Significant Unmet Need in HFrEF

Proprietary market research suggests need for novel therapy



Market research suggests need for novel therapy

Physicians say newly approved therapies have prolonged survival, decreased hospital visits, but still **see need for other therapies that reduce mortality**




Drugs that do not affect renal function

Most physicians recognize negative effect therapies such as aldosterone antagonists have **on renal function**



Drugs that do not affect BP

BP often limiting factor for up titration and therapy initiation
Need efficacious drugs **that do not result in hypotension**



Drugs that enhance cardiac performance

Need drugs that target **novel/more specific molecular targets**
Need targets other than the neurohormonal pathway



Disease modifying therapies

Need drugs that safely enhance contractility
Increased EF most frequently mentioned desired measure



Drugs that increase QoL

Patient management will improve **with drugs that increase QoL**
Patient QoL decreases as they lose the ability to perform daily tasks

Pivotal Phase 3 Trial Design

Second largest clinical trial ever conducted in heart failure

Overview

Enrolled 8,256 patients at ~1,000 sites in 35 countries

Primary Endpoint

Composite of time to cardiovascular (CV) death or first HF event*, whichever occurs first

Secondary Endpoints

- Time to CV death
- Change in Kansas City Cardiomyopathy Questionnaire Total Symptoms Score (KCCQ TSS) from baseline to Week 24
- Time to first HF hospitalization
- Time to all-cause death



*An HF event defined as the presentation of the subject for an urgent, unscheduled clinic/office/ED visit, or hospital admission, with a primary diagnosis of HF, where the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives initiation or intensification of treatment specifically for HF (Hicks et al, 2015). Changes to oral diuretic therapy do not qualify as initiation or intensification of treatment.

Baseline Characteristics

Characteristic	OM (N=4120)	Placebo (N=4112)
<i>Demographics</i>		
Age (years), median (Q1, Q3)	66 (58, 73)	66 (58, 73)
Sex, female, n (%)	875 (21.2)	874 (21.3)
White/Asian/Black/other, %	78/9/7/7	78/9/7/7
<i>Heart Failure History and Medical Conditions</i>		
LVEF (%), mean (SD)	26.6 (6.3)	26.5 (6.3)
NYHA class, II/III/IV, %	53/44/3	53/44/3
Ischemic etiology, %	53.2	54.0
Atrial fib/flutter at screening, %	27.8	26.7
Type 2 diabetes, %	40.1	40.3


Characteristic	OM (N=4120)	Placebo (N=4112)
<i>Vitals and Laboratory Parameters</i>		
NT-proBNP (pg/mL), median (Q1, Q3)	1977 (980, 4061)	2025 (1000, 4105)
SBP (mmHg), mean (SD)	116 (15)	117 (15)
Heart rate, mean (SD)	72 (12)	72 (12)
eGFR (mL/min/1.73m ²), median (Q1, Q3)	59 (44, 74)	59 (44, 74)
Cardiac TnI (ng/mL), median (Q3)	0.027 (0.052)	0.027 (0.052)
<i>Medications and Cardiac Devices</i>		
ACEI/ARB/ARNi, %	87	87
ARNi, %	20	19
BB, %	94	94
MRA, %	78	78
SGLT2i, %	2.5	2.8
CRT, %	14	14
ICD, %	32	31

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; BB, beta blocker; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; fib, fibrillation; hsTnI, high-sensitivity troponin I; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; Q, quartile; SBP, systolic blood pressure; SGLT2i, sodium-glucose co-transporter 2 inhibitor.


Positive Primary Composite Endpoint

Treatment effect increased in more advanced patients

8% Relative Risk Reduction in Primary Composite Endpoint (Time to First Heart Failure Event or CV Death)¹



Treatment Effect Increased Progressively As Baseline LVEF Decreased²




AEs and treatment discontinuation balanced between treatment arms

1. Teerlink JR et al., Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure; N Eng J Med 2020, 384:105-116.
2. Teerlink JR., Diaz R., Felker GM., et al. Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. JACC. 2021

Greater Treatment Effect in Worsening HF









Primary Outcome in Severe HF: HR = 0.80 (0.71, 0.90)

(Severe HF defined as NYHA III-IV, EF ≤30%, HF hosp <6 mos)^{1,2}



Primary Outcome in Patients with LVEF ≤28%:

HR 0.84; 95% CI 0.77, 0.92


Subgroup	No. of Events/ No. of Patients		Hazard Ratio (95% CI)	Norm p-value	ARR
All Patients	3103/8232		0.92 (0.86, 0.99)	0.025	2.1%
LVEF ≤28%	1821/4456		0.84 (0.77, 0.92)	<0.001	4.9%
Outpatients	1255/3304		0.83 (0.75, 0.93)	0.001	5.0%
Inpatients	566/1152		0.86 (0.73, 1.02)	0.084	3.9%
Hosp <3 mos	1200/2688		0.83 (0.74, 0.93)	0.001	5.2%
Class III/IV	1055/2132		0.80 (0.71, 0.90)	<0.001	7.0%
NT-proBNP >2000	1249/2431		0.77 (0.69, 0.87)	<0.001	8.1%
SBP <110	843/1820		0.81 (0.70, 0.92)	0.002	7.4%

0.5 0.8 1.0 1.2
OM Better ← Placebo Better

1. Felker GM, Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from GALACTIC-HF, ESC Heart Failure 2021, June 2021
2. Felker GM, et al. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. JAMA Cardiology, October 2021.

Greater Treatment Effect in Patients with Low Blood Pressure

Patients with Low BP at high risk of CV death & HF events, often hard to treat




- 1,473 patients (17.9%) had low BP (\leq 100 mmHg)
- Greater treatment effect observed from *omecamtiv mecarbil* in patients with low BP on the primary composite endpoint with **absolute risk reduction of 9.8 events per 100 patient-years**
- Patients with low BP also had improvements in BP over time
- Measures of safety and tolerability were similar between patients with low BP and those without low BP

Metra M, "Effects of *Omecamtiv Mecarbil* in Patients with HFrEF and Low Blood Pressure: Results from GALACTIC-HF", Heart Failure 2022, May 2022

Laboratory and Safety Events

Variable	<i>Omecamtiv Mecarbil</i> (N=4110)	Placebo (N=4101)	Relative Risk or Difference (95% CI)
<i>Laboratory value change from baseline to Week 24</i>			
Systolic blood pressure – mmHg, mean (SD)	1.4 (15.3)	1.5 (15.6)	-0.1 (-0.9, 0.6)
Heart rate, bpm, mean (SD)	-2.1 (12.6)	-0.5 (12.8)	-1.6 (-2.2, -1.0)
Cardiac Troponin I, ng/L, median (Q1, Q3)	0.004 (-0.002, 0.021)	0.000 (-0.009, 0.008)	0.004 (0.003, 0.005)
NT-proBNP, pg/mL, median (Q1, Q3)	-251 (-1180, 295)	-180 (-915, 441)	0.90 (0.86, 0.94)
<i>Adverse events (AEs)</i>			
Any serious AE, n (%)	2373 (57.7)	2435 (59.4)	0.97 (0.94, 1.01)
Drug discontinuation due to AE, n (%)	371 (9.0)	382 (9.3)	0.97 (0.85, 1.11)
Adverse events of interest			
Ventricular tachyarrhythmias	290 (7.1)	304 (7.4)	0.95 (0.82, 1.11)
Torsade de pointes/QT prolongation	176 (4.3)	195 (4.8)	0.90 (0.74, 1.10)
SAE of ventricular arrhythmia requiring treatment	119 (2.9)	127 (3.1)	0.93 (0.73, 1.20)
Adjudicated major cardiac ischemic events, n (%)	200 (4.9)	188 (4.6)	1.06 (0.87, 1.29)
Myocardial infarction	122 (3.0)	118 (2.9)	
Hospitalized for unstable angina	25 (0.6)	12 (0.3)	
Coronary revascularization	115 (2.8)	117 (2.9)	
Adjudicated Strokes	76 (1.8)	112 (2.7)	0.68 (0.51, 0.91)

Large and Growing Heart Failure Patient Population



Proposed Omecamtiv Mecarbil Target Patient

Worsening signs and symptoms of heart failure requiring intensification of treatment despite periods of stabilization on GDMT

Cardiac Function



LVEF ≤ 30%

+

Recent Event



HF Event*
≤ 12 months

+ / -

GDMT Limitations



Co-morbidities
and/or tolerability**

* HF Event: Urgent, unscheduled outpatient visit or hospitalization ** Due to renal impairment, low BP and/or hyperkalemia

1. National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) as accessed 4/1/2019 at website. <https://www.cdc.gov/nchs/nhanes/>. – data from 2013-2016 as quotes in Benjamin 2019 Circulation. 2019;139:e56–e528. DOI: 10.1161/

2. EF based on distribution as presented in Dunlay et al Circ Heart Fail. 2012;5:720-726,


3. 2.1% annual growth rate:1.9% annual growth rate of patient population 65+ (UN World Populations Prospects Nov 2019) and a 0.2% mortality impact of HF treatment (doi: 10.1136/bmj.l223 | BMJ 2019;364:l223)

High Cost Burden Primarily Due to Hospitalizations

Omecamtiv mecarbil reduced clinical events, resource utilization & costs related to HF events

Over next decade, HF cost burden is expected to **increase over half**

US HF Burden (\$B)



Mostly due to cycle of **hospitalizations** and re-admissions

Mean cost for **each** hospital stay of ~\$17K³

HF-associated costs of initial hospitalization and 12 months following discharge ~\$35K⁴

Of total lifetime HF cost burden, ~**80% due to hospital stays**⁵

Outpatient HF-related **drug costs only ~2-3%** of the total HF-related costs⁴

Omecamtiv mecarbil **reduced costs** related to HF events in patient subgroup*

Treatment with *omecamtiv mecarbil* associated with significant reductions in risk of first HF event, **total HF events** and cumulative HF events

Estimated cost reductions related to HF events were **\$3,085, a 19% reduction per patient**

Of the cost reductions, 99% due to HF **hospitalizations avoided**

* Subgroup of 5,369 patients (65%) of the 8,256 patients enrolled in GALACTIC-HF excluding those with digoxin & atrial fibrillation or with EF >30%

1. Urbich, M., Globe, G., Pantiri, K. et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). *PharmacoEconomics* 38, 1219–1236 (2020). <https://doi.org/10.1007/s40273-020-00952-0>

2. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail.* 2013;6(3):606–19. <https://doi.org/10.1161/HHF.0b013e318291329a>.

3. Gaziano et al, *AMA Cardiol.* 2016;1(6):666–672. doi:10.1001/jamcardio.2016.1747

4. Givertz, M. M., Yang, M., Hess, G. P., Zhao, B., Rai, A., and Butler, J. (2021) Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. *ESC Heart Failure*, 8: 1915– 1923. <https://doi.org/10.1002/ehf2.13155>

5. Dunlay SM, Shah ND, Shi Q, Morlan B, VanHouten H, Long KH, Roger VL. Lifetime costs of medical care after heart failure diagnosis. *Circ Cardiovasc Qual Outcomes.* 2011 Jan 1;4(1):68–75. doi: 10.1161/CIRCOUTCOMES.110.957225. Epub 2010 Dec 7

Omecamtiv Mecarbil: Value Proposition

In HFrEF, patients with lower ejection fractions are hospitalized more often

In HFrEF, every 10 points lower EF, is proven to drive higher events and risk of increased hospitalizations¹

Hospitalization reductions seen in clinical trial of *omecamtiv mecarbil*

Clinically meaningful and statistically significant hospitalization reductions seen among worsening HF patients with EF \leq 30²



Our access activities may demonstrate economic value of *omecamtiv mecarbil*

Partnering with key institutions to generate **real world evidence** of unmet needs in patients with lower ejection fractions

Using **HEOR** and clinical results to demonstrate the economic impact and value


Building Market Access team holding early discussions with **payers**

1. Based on Solomon S. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients, Circulation 2005


2. Felker GM. ESC Heart Fail 2021 Oral Presentation. Data based on post hoc analyses.

Small Subset of Cardiologists Manage Majority of Patients

HFrEF Patient Concentration in Cardiologists



Distribution of High-Volume Cardiologists




Allows for more targeted field team approach, focusing on <10,000 HCPs

Symphony APLD (1/1/2019 – 12/31/2020); Physician Interviews; Analysis includes **n = 25,510 cardiologists** and **n = 110,114 PCPs** who see **at least 1 HFrEF patient** during the two-year market map period

Medicare Is Major Payer with Select Key Players

Medicare is largest payer; enrollment highly concentrated with nearly 3 of 4 patients in only 5 plans




Sources: National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017; Agarwal, Fanarow, and Ziaieian; JAMA Cardiol, Feb 10, 2021 (Table 2 Payer Status); <https://www.kff.org/medicare/issue-brief/10-things-to-know-about-medicare-part-d-coverage-and-costs-in-2019/>; IQVIA LAAD data. SGLT-2 US Market Access Assessment, IQVIA. 1/7/2020


Gated Build of Commercial Infrastructure

Majority of spending to occur post-approval

2/3 of hiring to occur post-approval



Activities initiated upon key de-risking events




Aficamten

In US, Large HCM Population With Many Undiagnosed

Currently
~280K diagnosed,
~190K oHCM
symptomatic patients

Estimated ~400-800K
un-diagnosed patients



nHCM: non-obstructive HCM; oHCM: obstructive HCM
CVRG market strategies heart failure 2Q 2021 and other sources on file

Aficamten: Aspirational Target Profile

Potential next-in-class cardiac myosin inhibitor



Efficacy

Functional Improvement: Improved exercise capacity

Symptom Improvement: One or two class improvement in **NYHA class**

Quality of Life: KCCQ improvement



Safety and Tolerability

Minimal drug-drug interactions

Maintain LVEF: >50% on vast majority of patients

Reversibility: Quickly reversible with titration down



Dosing

Titration: Time to optimal dose, ~2-week titration intervals using echocardiography

No monitoring of plasma concentrations


Product not FDA approved, aspirational profile dependent on phase 3 data
Aficamten is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product has not been established.

REDWOOD-HCM: Cohorts 1 & 2

Patients with symptomatic oHCM on background therapy excluding *disopyramide*



Two sequential dose-finding cohorts



Patient Enrollment and Dosing

Cohorts 1 & 2



41 Total Enrolled Patients

		Final Dose Achieved (N)				
		5 mg	10 mg	15 mg	20 mg	30 mg
N = 14	Cohort 1	4	5	5		
N = 14	Cohort 2		9		4	1

Baseline Characteristics

Cohorts 1 & 2




Characteristic	Placebo (n = 13)	<i>Aficamten</i> (n = 28)
Age (Years) , Mean (SD) [Range]	57.2 (9.6) [36,69]	56.6 (13.6) [33,78]
< 65 Years	10 (77%)	17 (61%)
Sex , n (%)		
Female	8 (62%)	15 (54%)
Race = White , n (%)	12 (92%)	28 (100%)
NYHA Class , n (%)		
Class II	11 (85%)	17 (61%)
Class III	2 (15%)	11 (39%)
Maximal LV Wall Thickness (mm) Mean (SD)	16 (3)	17 (3)
LVEF* at Screening (%), Mean (SD)	73.6 (5.9)	71.7 (8.0)
LVOT-G*, Rest at Screening (mmHg), Mean (SD)	70.0 (28.0)	61.1 (29.8)
LVOT-G*, Valsalva at Screening (mmHg), Mean (SD)	93.3 (27.2)	89.3 (31.5)

* Site-read echocardiogram

Maron M, Abraham T, Masri A, et al. "REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, *Aficamten*, In Obstructive Hypertrophic Cardiomyopathy"

Response Rates on Treatment with *Aficamten*

Cohorts 1 & 2



- Consistent, **clinically meaningful reductions in LVOT gradients** within two weeks
- **No treatment interruptions** or discontinuations
- No treatment-related SAEs
- **Reversibility of drug effect** demonstrated
- Statistically significant reductions in NT-proBNP
- Improvement in NYHA class


Maron M, Abraham T, Masri A, et al. "REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, *Aficamten*, In Obstructive Hypertrophic Cardiomyopathy" *Aficamten* is an investigational agent and has not been approved for use by the U.S. Food & Drug Administration (FDA) or any regulatory agency. The safety and effectiveness of this product has not been established.

REDWOOD-HCM: Efficacy

Cohorts 1 & 2



Reductions in LVOT gradients



Dose finding study
Cohort 1 (n=21), Cohort 2 (n=20)


Maron M, Abraham T, Masri A, et al. "REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy"

Change from Baseline in NT-proBNP & NYHA Class

Cohorts 1 & 2



Change from Baseline NT-proBNP to Week 10




* $p = 0.003$ for Pooled Cohort 1 & 2 vs. Placebo

■ Combined Placebo (N=13)
 ■ Aficamten: Cohort 1 (N=14)
 ■ Aficamten: Cohort 2 (N=14)

Improvement in Heart Failure Symptoms (NYHA Class)

Week 10 Responder Definition: Improvement in NYHA Class ≥ 1



Cohort 1 vs Placebo: $p > 0.1$
 Cohort 2 vs Placebo: $p = 0.08$

■ No Improvement in NYHA Class
 ■ ≥ 1 NYHA Class Improvement

Maron M, Abraham T, Masri A, et al. "REDWOOD-HCM: A Randomized, Double-blind, Placebo-controlled, Dose-finding Trial of the Cardiac Myosin Inhibitor, Aficamten, In Obstructive Hypertrophic Cardiomyopathy"

Improved Cardiac Structure and Diastolic Function



Cohorts 1 & 2: Early signs of improvement in cardiac structure and myocardial relaxation





Treatment with *aficamten* for 10 weeks resulted in:

- **Significant reduction in left atrial volume index**
- Trend towards a **reduction in LV mass index**
- **Improved diastolic function**
 - reduction in lateral E/e' ($p < 0.01$)
 - increase in lateral e' ($p < 0.05$)

Cardiac Structure



Diastolic Function




REDWOOD-HCM: Cohort 4

Patients with symptomatic nHCM on background therapy



Opened to enrollment in Q1 2022; results expected 1H 2023



hs-cTnI: high-sensitivity cardiac troponin

*Telephone visits




**Patient can only be down-titrated at Week 6

REDWOOD-HCM: Open Label Extension

Initial data through 24 weeks shows improvement in LVOT-G, NYHA class



Treatment was well-tolerated: one temporary discontinuation, one temporary down-titration (neither related to treatment)



Data presented as mean \pm 95% Confidence Interval

REDWOOD-HCM OLE is enrolling patients who complete REDWOOD-HCM and SEQUOIA-HCM

SEQUOIA-HCM: Phase 3 Trial



Plan to enroll at >100 sites in US, Europe and Asia**

Primary endpoint: **Change in pVO₂ by CPET from baseline to Week 24**

Secondary objectives include measuring **change in KCCQ & improvement in NYHA class at week 12 and 24**


Enrolling 270 patients treated with standard of care with:

- **resting LVOT-G ≥30 mmHg,**
- **post-Valsalva LVOT-G ≥50 mmHg,**
- **NYHA Class II or III,**
- **exercise performance <80% predicted**

Individualized dose up-titration based on echocardiography: LVEF ≥55%, post-Valsalva LVOT-G ≥30 mmHg


* Focused echocardiogram

** Plan to enroll in US, Italy, France, Germany, Czech Republic, Denmark, Hungary, Netherlands, Poland, Portugal, Spain, UK, Israel & China
SOC: standard of care




Aficamten: Clinical Development Plan for HCM

SEQUOIA-HCM enrolling patients with oHCM; REDWOOD-HCM Cohort 4 enrolling patients with nHCM



Novel Approach May Address Multiple Unmet Patient Needs



Sarcomere Directed Drug Commercialization

FRANCHISE STRATEGY

Go-to-Market Synergies for *Omecamtiv Mecarbil* & *Aficamten*

Sales Team	Given target overlap, leveraging same sales team	→ Synergy PV of ~ \$500M
Commercial Support Functions	Utilize resources across brands (e.g., access, analytics, ...)	
Medical Affairs	MSLs qualified to cover both HFrEF and HCM	
Corporate Support Functions	Avoid costs of duplication (IT, Finance, HR, ...)	

Limited Incremental Cost For Future U.S. CV Launches

Building Today ...

To optimize value capture for potential launch of *omecamtiv mecarbil*

- Building deep, long-term relationships

... To Lead Tomorrow

To support future launches and establish Cytokinetics as a CV leader

- Significant overlap between HFrEF and HCM



<1,000

Hospitals
& HF Clinics




<10,000

Cardiologists




~15%

Additional
Targets



Coverage of
vast majority
of HCM


Expanding Franchise Reach in Key Geographies



Europe: Seek co-development and co-commercialization partnership for *omecamtiv mecarbil*; pursue bridge to independent go-to-market strategy for *aficamten* in certain countries in Europe



Japan: Seek partnership for *omecamtiv mecarbil* and *aficamten* enabling parallel franchise strategy



Sarcomere Directed Drug Development

SKELETAL MUSCLE

Reldesemtiv

Reldesemtiv

Phase 2 Clinical Trial in ALS


Results presented at American Academy of Neurology 2019 Annual Meeting

Parallel group, dose ranging study enrolled 458 patients with ALS in the US, Canada, Australia and Europe evaluating change from baseline in the percent predicted slow vital capacity (SVC) at 12 weeks of treatment with *reldesemtiv* or placebo



Primary Endpoint: SVC

Change from baseline in percent predicted SVC at week 12



Primary Analysis*


P = 0.11
for weighted
dose-response
relationship

*Based on Mixed Model for Repeated Measures (MMRM) with the contrasts of (-5, -1, 3, 3) for placebo, *reldesemtiv* 150 mg, 300 mg and 450 mg BID, respectively


Phase 2 Clinical Trial

Primary analysis not statistically significant; patients on all doses of *reldesemtiv* declined less than patients on placebo*

SVC Change From Baseline (All Active vs Placebo)




ALSFRS-R Change From Baseline (All Active vs Placebo)




*post hoc analysis
FORTITUDE-ALS did not achieve statistical significance, but patients on all dose groups of *reldesemtiv* declined less than patients on placebo

Subgroup Analyses*

Percent Predicted SVC




ALSFRS-R Total Score



*FORTITUDE-ALS did not achieve statistical significance, but patients on all dose groups of *reldesemtiv* declined less than patients on placebo

Post-Hoc Analyses Inform Potential Path Forward


Change From Baseline in ALSFRS-R by Progressor Tertiles



SP: slow progressor; MP: middle progressor; FP: fast progressor

Probability of No New DME Over Time With Treatment With *Reldesemtiv*


DME (Durable Medical Equipment): Manual wheelchair, power wheelchair, NIV, Augmentative Language Device, PEG



Phase 3 Clinical Trial Design

>70 centers activated, >150 patients enrolled; interim analysis for futility in Q4 2022

Enrolling patients with ALS in the US, Canada, Australia and Europe evaluating change from baseline ALSFRS-R at 24 weeks of treatment with *reldesemtiv* or placebo



Study Visits	Screen	D1	W2	W4	W8	W12	W16	W20	W24	W26	W28	W32	W36	W40	W44	W48	W52 FU
ALSFRS-R	↑	↑		↑	↑	↑	↑	↑	↑		↑	↑	↑	↑	↑	↑	↑
FVC	↑	↑		↑	↑	↑	↑	↑	↑		↑	↑	↑	↑	↑	↑	↑
Lab	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑	↑
Muscle Strength	↑	↑		↑		↑			↑				↑			↑	↑

↑ In-Clinic




↑ Remote

↑ Both In-Clinic & Remote

Sarcomere Directed Therapies

CORPORATE PROFILE


Robust Pipeline, Solid Financial Position

Pipeline	1	Potential commercial launch in 2023	2	Programs in Phase 3 trials	3	Potential FDA approvals by 2025	5	Clinical stage programs	10	Development programs by 2025
Programs	Heart Failure <i>Omecamtiv mecarbil</i> <ul style="list-style-type: none">Positive trial results from GALACTIC-HFNDA filed; PDUFA 02/28/23		 CK-136 <ul style="list-style-type: none">Phase 1	HCM <i>Aficamten</i> <ul style="list-style-type: none">Phase 3 trial SEQUOIA-HCM, enrolling patients with oHCMCohort 4 of Phase 2 trial REDWOOD-HCM enrolling patients with nHCM		ALS <i>Reldesemtiv</i> <ul style="list-style-type: none">Phase 3 trial, COURAGE-ALS ongoing		Ongoing R&D Additional research in muscle biology, energetics & metabolism		
Foundations			350 Full time employees		\$596.7M At Q2 2021		>2 years Cash runway			

Timelines and milestones reflect Cytokinetics' current expectations and beliefs

Monetizing Our Pipeline to Bolster Balance Sheet

Symmetry of deals for *omecamtiv mecarbil* and *aficamten* affords synergies for development and potential launches and supports franchise strategies



* 4.5% on worldwide net sales of *omecamtiv mecarbil* (and potentially other compounds with same mechanism of action), subject to potential increase of up to an additional 1% under certain circumstances

** 4.5% for annual worldwide net sales of *aficamten* up to \$1 billion and 3.5% for annual worldwide net sales of *aficamten* in excess of \$1 billion, subject to reduction in certain circumstances

Balance Sheet & Financial Guidance

2022 Condensed Balance Sheet

As of 6/30/2022

in millions

	Total
Cash and investments	\$596.7
Accounts receivable	\$2.0
PPE	\$78.6
Leased assets	\$72.2
Other assets	\$22.2
Total Assets	\$771.7
Debt	\$134.0
Liability related to sale of future royalties	\$282.3
Deferred Revenue	\$0
Lease liability	\$127.0
Other liabilities	\$117.0
Total Liabilities	\$660.3
Working capital	\$535.5
Accumulated deficit	(\$1,306.3)
Stockholders' equity	\$111.4
Wtd Avg Basic Shares Outstanding	85.4

2022 Financial Guidance

in millions

	Total
Cash Revenue	\$20 – 25
Cash Operating Expenses	\$375– 385
Net	~ \$360 - 365

Expected Upcoming Milestones

Participate in **Advisory Committee meeting for *omecamtiv mecarbil*** on December 13, 2022

Launch *omecamtiv mecarbil* in the U.S. subject to FDA approval in Q1 2023

Continue enrollment in **SEQUOIA-HCM** through 2022; results expected 2H 2023

Begin second Phase 3 **trial of *aficamten* in oHCM** in Q4 2022

Present additional long-term data from **REDWOOD-HCM OLE** in 2H 2022

Continue enrollment in **Cohort 4 of REDWOOD-HCM** in 2022; Results expected 1H 2023

Expect **first interim analysis from COURAGE-ALS** in Q4 2022



THANK YOU

Sarcomere Directed Therapies



Nefertari, diagnosed with heart failure



Jillian, diagnosed with HCM



Chuck, diagnosed with ALS